CRL241220P190000
- 8.05
- 0.000.00%
Charles River Newsroom
Express News | Shares of IQVIA, Charles River and ICON PLC Down Between 2% and 3%
Express News | Shares of Contract Drug Researchers Fall After Rfk Jr Picked for Top US Health Agency Role
Eminence Capital Buys Gitlab, Charles River, Exits Haleon, Others in Q3
Independent Director Richard Wallman Sold A Bunch Of Shares In Charles River Laboratories International
Charles River Laboratories International Insider Sold Shares Worth $1,647,418, According to a Recent SEC Filing
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Charles River Labs Is Maintained at Hold by TD Cowen
Charles River (CRL) International Revenue in Focus: Trends and Expectations
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $227
Charles River Laboratories to Present at UBS and Jefferies Conferences
There's Reason For Concern Over Charles River Laboratories International, Inc.'s (NYSE:CRL) Price
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $227
Morgan Stanley Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $225
Morgan Stanley Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $225
J.P. Morgan Sticks to Its Hold Rating for Charles River Labs (CRL)
Hold Rating for Charles River Labs Amid Mixed Performance and Market Uncertainties
Charles River Laboratories International Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Baird Adjusts Charles River Laboratories International Price Target to $211 From $190, Maintains Neutral Rating
Charles River Labs Price Target Raised to $225.00/Share From $190.00 by Evercore ISI Group
Charles River Labs Is Maintained at In-Line by Evercore ISI Group